The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
TP53 and gastric carcinoma: A review
Abstract
In this article, we survey the major p53 (TP53) alterations identified in gastric carcinomas and their precursors. These include p53 expression, mutations, and loss of heterozygosity (LOH). Not only are the various abnormalities summarized, but in addition there is a survey of the literature with respect to the impact of these changes on patient prognosis and treatment response. The majority of published studies involve the immunohistochemical detection of the protein. These use different antibodies, different detection techniques, and different methods of interpretation. Therefore not surprisingly, the results of many of the studies are contradictory with one another. Overall, however, it appears that p53 alterations occur early in the development of gastric carcinoma, being present even in the nonneoplastic mucosa and they increase in frequency as one progresses along the pathway of gastric carcinoma development. p53 immunoreactivity is seen in 17%-90.7% of invasive gastric carcinomas. p53 alterations occur much more commonly in proximal lesions than in distal ones, suggesting that the molecular events leading to the development of gastric carcinoma may be very different in proximal vs. distal tumors. p53 mutations occur in 0%-77% of gastric carcinomas. The mutations are distributed widely across the gene from exons 4-11 with hot spots of mutation at codons 175, 248, 273, 282, 245, and 213. G:C>A:T transitions at CpG sites are the commonest type of mutation. At least 60% of carcinomas with mutations also exhibit p53 LOH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
LAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
A human model of gastric carcinogenesis.
Corréa, P. (1988) · PubMed · Cited by 1,433
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
DNA Deaminating Ability and Genotoxicity of Nitric Oxide and its Progenitors
Wink, D. A., Kasprzak, K. S., Maragos, C. M., Elespuru, R. K., Misra, M., Dunams, T. M., Cebula, T. A., Koch, W. H., Andrews, A. W., Allen, J. S., et al. (1991) · Science · doi:10.1126/science.1948068 · Cited by 1,234
DNA damage and mutation in human cells exposed to nitric oxide in vitro.
Nguyen, T., Brunson, D., Crespi, C. L., Penman, B. W., Wishnok, J. S., & Tannenbaum, S. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3030 · Cited by 974
Sheffield, V. C., Beck, J. S., Kwitek, A. E., Sandstrom, D. W., & Stone, E. M. (1993) · Genomics · doi:10.1006/geno.1993.1193 · Cited by 673
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
An immunochemical analysis of the human nuclear phosphoprotein p53
Vojtěšek, B., Bártek, J., Midgley, C. A., & Lane, D. P. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90122-a · Cited by 531
(2011) · Hepatogastroenterology · doi:10.5754/hge11232 · Cited by 511
Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Vogelstein, B., & Hamilton, S. R. (1994) · The Journal of Pathology · doi:10.1002/path.1711720104 · Cited by 505
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Regulation of p53 function and stability by phosphorylation.
Ashcroft, M., Kubbutat, M. H. G., & Vousden, K. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1751 · Cited by 452
p53 expression and prognosis in gastric carcinoma
Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., & Silvestre, F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500604 · Cited by 321
Mai, U. E., Perez-Perez, G. I., Wahl, L. M., Wahl, S. M., Blaser, M. J., & Smith, P. D. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115095 · Cited by 287
Tamura, G., Kihana, T., Nomura, K., Terada, M., Sügimura, T., & Hirohashi, S. (1991) · PubMed · Cited by 228
Prognostic significance of p53 overexpression in gastric and colorectal carcinoma
Starzynska, T., Bromley, M., Ghosh, A., & Stern, P. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.314 · Cited by 226
Nuclear localization is essential for the activity of p53 protein.
Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., & Rotter, V. (1991) · PubMed · Cited by 192
p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail.
Strickler, J. G., Zheng, J., Shu, Q., Burgart, L. J., Alberts, S. R., & Shibata, D. K. (1994) · PubMed · Cited by 181
Molecular markers in male breast carcinoma
Rayson, D., Erlichman, C., Suman, V. J., Roche, P. C., Wold, L. E., Ingle, J. N., & Donohue, J. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981101)83:9<1917::aid-cncr6>3.0.co;2-1 · Cited by 149
Soong, R., Robbins, P., Dix, B. R., Grieu, F., Lim, B. H. G., Knowles, S., Williams, K. E., Turbett, G. R., House, A. K., & Iacopetta, B. J. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90282-8 · Cited by 147
Molecular biological observations in gastric cancer.
Tahara, E., Semba, S., & Tahara, H. (1996) · PubMed · Cited by 145
Maesawa, C., Tamura, G., Suzuki, Y. A., et al. (1995) · The Journal of Pathology · doi:10.1002/path.1711760307 · Cited by 137
Occurrence of p53 Gene Abnormalities in Gastric Carcinoma Tumors and Cells Lines
Kim, J., Takahashi, T., Chiba, I., Park, J.-G., Birrer, M. J., Roh, J. K., Lee, H. D., Kim, J.-P., Minna, J. D., & Gazdar, A. F. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.13.938 · Cited by 132
Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach
Semba, S., Yokozaki, H., Yamamoto, S., Yasui, W., & Tahara, E. (1996) · Cancer · Cited by 131
Feng, C. W., Wang, L., Jiao, L. H., Liu, B., Zheng, S., & Xie, X. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-8 · Cited by 125
Stemmermann, G. N., Heffelfinger, S. C., Noffsinger, A. E., Hui, Y. Z., Miller, M. A., & Fenoglio‐Preiser, C. M. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90056-6 · Cited by 122
Self-citationHongyo, T., Buzard, G. S., Palli, D., Weghorst, C. M., Amorosi, A., Galli, M., Caporaso, N. E., Fraumeni, J. F., & Rice, J. M. (1995) · PubMed · Cited by 121
Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer
Leung, W. K., To, K., Ng, Y.-P., Lee, T.-L., Lau, J. Y. W., Chan, F. K. L., Ng, E. K. W., Chung, S., & Sung, J. J. �. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1607 · Cited by 109
Base transitions are the most frequent genetic changes at P53 in gastric cancer.
Renault, B., van den Broek, M., Fodde, R., Wijnen, J., Pellegata, N. S., Amadori, D., Khan, P. M., & Ranzani, G. N. (1993) · PubMed · Cited by 105
Boku, N., Chin, K., Hosokawa, K., Ohtsu, A., Tajiri, H., Yoshida, S., Yamao, T., Kondo, H., Shirao, K., Shimada, Y., et al. (1998) · PubMed · Cited by 104
Joypaul, B. V., Hopwood, D., Newman, E., Qureshi, S. S., Grant, A., Ogston, S., Lane, D. P., & Cuschieri, A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.182 · Cited by 101
Gleeson, C., Sloan, J., McManus, D. T., Maxwell, P., Arthur, K., McGuigan, J., Ritchie, A. J., & Russell, S. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.44 · Cited by 95
Allelotype of gastric adenocarcinoma.
Yustein, A. S., Harper, J., Petroni, G. R., Cummings, O. W., Moskaluk, C. A., & Powell, S. M. (1999) · PubMed · Cited by 93
Yasui, W., Akama, Y., Kuniyasu, H., Yokozaki, H., Semba, S., Shimamoto, F., & Tahara, E. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199610)180:2<122::aid-path647>3.0.co;2-c · Cited by 90
The clinical significance of p53 aberrations in human tumours
Bòsari, S., & Viale, G. (1995) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00203389 · Cited by 90
Hibi, K., Mitomi, H., Koizumi, W., Tanabe, S., Saigenji, K., & Okayasu, I. (1997) · American Journal of Clinical Pathology · doi:10.1093/ajcp/108.1.26 · Cited by 90
Joypaul, B. V., Newman, E. L., Hopwood, D., Grant, A., Qureshi, S. S., Lane, D. P., & Cuschieri, A. (1993) · The Journal of Pathology · doi:10.1002/path.1711700310 · Cited by 82
Microsatellite instability and mutations of p53 and TGF-‚ RII genes in gastric cancer
Renault, B., Calistri, D., Buonsanti, G., Nanni, O., Amadori, D., & Ranzani, G. N. (1996) · Human Genetics · doi:10.1007/s004390050267 · Cited by 74
Tanière, P., Martel-Planche, G., Maurici, D., Lombard‐Bohas, C., Scoazec, J., Montesano, R., Berger, F., & Hainaut, P. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63941-7 · Cited by 69
Matozaki, T., Sakamoto, C., Suzuki, T., Matsuda, K., Uchida, T., Nakano, O., Wada, K., Nishisaki, H., Konda, Y., & Nagao, M. (1992) · PubMed · Cited by 65
Kubicka, S., Claas, C., Staab, S., Kühnel, F., Zender, L., Trautwein, C., Wagner, S., Rudolph, K. L., & Manns, M. P. (2002) · Digestive Diseases and Sciences · doi:10.1023/a:1013275706401 · Cited by 56
Missense mutations and a deletion of the p53 gene in human gastric cancer
Matozaki, T., Sakamoto, C., Matsuda, K., Suzuki, T., Konda, Y., Nakano, O., Wada, K., Uchida, T., Nishisaki, H., Nagao, M., et al. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80133-0 · Cited by 56
Expression of p53 protein as a prognostic factor in patients With gastric cancer
Victorzon, M., Nordling, S., Haglund, C. H., Lundin, J. E., & Roberts, P. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00547-1 · Cited by 53
Shiao, Y., Palli, D., Caporaso, N. E., et al. (2000) · PubMed · Cited by 52
Murakami, K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750026191 · Cited by 45
Liu, X. P., Tsushimi, K., Tsushimi, M., Kawauchi, S., Oga, A., Furuya, T., & Sasaki, K. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00589-4 · Cited by 41
Genetic alterations in gastric cancers from British patients
Sud, R., Wells, D., Talbot, I. C., & Delhanty, J. D. A. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00397-6 · Cited by 38
Rugge, M., Shiao, Y., Busatto, G., Cassaro, M., Strobbe, C., Russo, V. M., Leo, G., Parenti, A. R., Scapinello, A., Arslan, P., et al. (2000) · Molecular Pathology · doi:10.1136/mp.53.4.207 · Cited by 38
Sakurai, S., Sano, T., & Nakajirna, T. (1995) · Pathology International · doi:10.1111/j.1440-1827.1995.tb03379.x · Cited by 32
Kaye, P., Radebold, K., Isaacs, S., & Dm, D. (2000) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0738 · Cited by 29
Shiao, Y., Palli, D., Buzard, G. S., Caporaso, N. E., Amorosi, A., Saieva, C., Fraumeni, J. F., Anderson, L. M., & Rice, J. M. (1998) · Carcinogenesis · doi:10.1093/carcin/19.12.2145 · Cited by 28
Danesi, D. T., Span�, M., Fabiano, A., Altavista, P., Pasqualetti, P., Toscano, M. G., Antonini, F., Catalano, P., Mecozzi, A., Picconi, A., et al. (2000) · Cytometry · Cited by 27
p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos
Schneider, B., Pekkel, V., Shelton, C. H., Pulitzer, D. R., Allred, D. C., Hilsenbeck, S. G., Hensel, C. H., Rodr�guez-Mart�nez, H. A., & C., M. E. G.-D. (1994) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00193499 · Cited by 26
A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis
Ogawa, M., Onoda, N., Maeda, K., Kato, Y., Nakata, B., Kang, S., Sowa, M., & Hirakawa, K. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.7.5.479 · Cited by 22
Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma
Iwamatsu, H., Nishikura, K., Watanabe, H., Ajioka, Y., Hashidate, H., Kashimura, H., & Asakura, H. (2001) · Gastric Cancer · doi:10.1007/s101200100012 · Cited by 20
Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation.
Ricevuto, E., Ficorella, C., Fusco, C., et al. (1996) · PubMed · Cited by 17
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation
(1993) · Lung Cancer · doi:10.1016/0169-5002(93)90516-z · Cited by 2
Cited by
Nitric oxide and cancer: a review
Korde Choudhari, S., Chaudhary, M., Bagde, S., Gadbail, A. R., & Joshi, V. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-118 · Cited by 634
Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Matsumoto, Y., Marusawa, H., Kinoshita, K., Endo, Y., Kou, T., Morisawa, T., Azuma, T., Okazaki, I.-M., Honjo, T., & Chiba, T. (2007) · Nature Medicine · doi:10.1038/nm1566 · Cited by 479
Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 365
Metadata
- Authors
- Fenoglio-Preiser, C. M., Wang, J., Stemmermann, G. N., & Noffsinger, A.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2003-02-27
- Volume
- 21
- Issue
- 3
- Pages
- 258-270
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W1966660119
- Cited by
- 252
- References
- 61
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.